🔗 Share this article World Health Organization Raises Warning Over Severe Lack of Obesity Injections Under 10% of individuals eligible to benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it issues its initial advice on the therapies. Given more than one billion individuals worldwide now obese, it is urging more widespread and fairer access to these injectable treatments. Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention. "Our new guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread availability to the treatments that can help people shift substantial weight, says the organization. Skinny Jab Supply Crisis Despite the present most favorable scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of the global need, per the WHO. The guideline calls on governments and firms to widen availability, via measures including licensing agreements. The intellectual property rights on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. How Obesity Injections Function The injections mimick a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people consume fewer calories. People usually start to lose weight after several weeks of starting on the regular doses. Evidence points to people may put most of the weight back on after a year of halting the drug, when their typical hunger return. To be carrying excess weight elevates your risk for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Excess weight concerns people in countries worldwide and was associated with millions of deaths worldwide in 2024, per the WHO.
Under 10% of individuals eligible to benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it issues its initial advice on the therapies. Given more than one billion individuals worldwide now obese, it is urging more widespread and fairer access to these injectable treatments. Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention. "Our new guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread availability to the treatments that can help people shift substantial weight, says the organization. Skinny Jab Supply Crisis Despite the present most favorable scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of the global need, per the WHO. The guideline calls on governments and firms to widen availability, via measures including licensing agreements. The intellectual property rights on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. How Obesity Injections Function The injections mimick a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people consume fewer calories. People usually start to lose weight after several weeks of starting on the regular doses. Evidence points to people may put most of the weight back on after a year of halting the drug, when their typical hunger return. To be carrying excess weight elevates your risk for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Excess weight concerns people in countries worldwide and was associated with millions of deaths worldwide in 2024, per the WHO.